News
SYNH
33.94
-0.29%
-0.10
Syneos Health, Inc.'s (NASDAQ:SYNH) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
With its stock down 48% over the past three months, it is easy to disregard Syneos Health (NASDAQ:SYNH). However, stock...
Simply Wall St. · 4d ago
Syneos Health to Participate in Fireside Chat at the 2022 Evercore ISI HealthCONx Conference
MORRISVILLE, N.C., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Michelle Keefe is scheduled to participate in a fireside cha...
GlobeNewswire · 11/17 21:44
Is it a Great Move to Invest in Syneos Health (SYNH)?
ClearBridge Investments, an investment management firm, published its “Small Cap Value Strategy” third-quarter 2022 investor letter – a copy of which can be downloaded here. The ClearBridge Small Cap Value Strategy underperformed its Russell 2000 Value Ind...
Insider Monkey · 11/11 04:06
Syneos Health (SYNH) Detracted From Performance in the Third Quarter
ClearBridge Investments, an investment management company, released its “ClearBridge Select Strategy” third quarter 2022 investor letter. A copy of the same can be downloaded here. The strategy outperformed its benchmark, the Russell 3000 Index, in the thi...
Insider Monkey · 11/09 16:05
Syneos Health (SYNH) Q3 Earnings Miss Estimates, '22 View Cut
Syneos Health (SYNH) Q3 revenues are below the guidance primarily due to the impact of lower net new business awards, delays in backlog conversion and customer delays in its FSP business.
Zacks · 11/09 14:52
--Deutsche Bank Adjusts Syneos Health Price Target to $51 From $77, Maintains Buy Rating
--Deutsche Bank Adjusts Syneos Health Price Target to $51 From $77, Maintains Buy Rating
MT Newswires · 11/09 08:57
--UBS Adjusts Syneos Health Price Target to $34 From $68, Maintains Neutral Rating
--UBS Adjusts Syneos Health Price Target to $34 From $68, Maintains Neutral Rating
MT Newswires · 11/08 10:27
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Benzinga · 11/08 10:00
Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday
Benzinga · 11/08 07:00
Why did Syneos Health stock surge today?
Seekingalpha · 11/07 21:00
Expert Ratings for Syneos Health
Benzinga · 11/07 16:24
Research Alert: CFRA Keeps Hold Opinion On Shares Of Syneos Health, Inc.
Research Alert: CFRA Keeps Hold Opinion On Shares Of Syneos Health, Inc.
MT Newswires · 11/07 14:31
Baird Maintains Outperform on Syneos Health, Lowers Price Target to $42
Benzinga · 11/07 13:29
Barclays Maintains Overweight on Syneos Health, Lowers Price Target to $30
Benzinga · 11/07 11:48
Citigroup Maintains Neutral on Syneos Health, Lowers Price Target to $30
Benzinga · 11/07 11:38
--Baird Adjusts Price Target on Syneos Health to $42 From $80, Maintains Outperform Rating
--Baird Adjusts Price Target on Syneos Health to $42 From $80, Maintains Outperform Rating
MT Newswires · 11/07 10:46
Yelp, Twilio, Atlassian, And Other Big Losers From Friday
Benzinga · 11/07 10:31
--Citigroup Adjusts Price Target on Syneos Health to $30 From $55, Maintains Neutral Rating
--Citigroup Adjusts Price Target on Syneos Health to $30 From $55, Maintains Neutral Rating
MT Newswires · 11/07 10:05
--Barclays Adjusts Price Target on Syneos Health to $30 From $60, Maintains Overweight Rating
--Barclays Adjusts Price Target on Syneos Health to $30 From $60, Maintains Overweight Rating
MT Newswires · 11/07 09:35
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
Benzinga · 11/07 08:07
More
Webull provides a variety of real-time SYNH stock news. You can receive the latest news about Syneos Health through multiple platforms. This information may help you make smarter investment decisions.
About SYNH
Syneos Health, Inc. is a biopharmaceutical solutions company. It provides a range of clinical and commercial services to customers in the pharmaceutical, biotechnology, and healthcare industries. It offers both stand-alone and integrated biopharmaceutical product development solutions ranging from Early Phase (Phase I) clinical trials to the full commercialization of biopharmaceutical products. It operates through two business segments: Clinical Solutions and Commercial Solutions. Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. The segment offers individual services including product development, project management, protocol development, investigational site recruitment, and clinical monitoring. The Commercial Solutions segment provides commercialization services, including deployment solutions, communication solutions, and consulting services.